Liquid Biopsy: From Basic Research to Clinical Practice
Macías M (1), Alegre E (2), Díaz-Lagares A (3), Patiño A (2), Pérez-Gracia JL (2), Sanmamed M (4), López-López R (3), Varo N (2), González A (5).
(1) Clínica Universidad de Navarra, Pamplona, Spain.
(2) Clínica Universidad de Navarra, Pamplona, Spain; The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
(3) Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS), CIBERONC, Santiago de Compostela, Spain; Roche-CHUS Joint Unit, University Clinical Hospital of Santiago (CHUS), Santiago de Compostela, Spain.
(4) Yale University School of Medicine, New Haven, CT, United States.
(5)Clínica Universidad de Navarra, Pamplona, Spain; The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
Liquid biopsy refers to the molecular analysis in biological fluids of nucleic acids, subcellular structures, especially exosomes, and, in the context of cancer, circulating tumor cells. In the last 10 years, there has been an intensive research in liquid biopsy to achieve a less invasive and more precise personalized medicine.
Molecular assessment of these circulating biomarkers can complement or even surrogate tissue biopsy. Because of this research, liquid biopsy has been introduced in clinical practice, especially in oncology, prenatal screening, and transplantation.
Here we review the biology, methodological approaches, and clinical applications of the main biomarkers involved in liquid biopsy.
CITA DEL ARTÍCULO Adv Clin Chem. 2018;83:73-119. doi: 10.1016/bs.acc.2017.10.003. Epub 2017 Nov 23